ERBB2 and breast carcinoma: Patients with early-stage breast cancer (ESBC) or localized invasive breast cancer have a much higher 5-year survival rate, with 99% for estrogen receptor positive (ER+), 94% for HER2+, and 85% for TNBC [3].